Investing.comCodex · 实盘不做把握 5/10不做原因:无增量信息
北京时间·🕒 发布 19:04:35·⟳ 抓取 19:06:04 +1m29s·⚡ 决策 09-01 20:18:25 +1h12m·56.0 天前
BlossomHill将于WCLC披露BH-30643肺癌试验更新数据，但当前未公布新疗效结果
当前信息的核心是未来会议数据披露预告，而不是临床数据本身；此前Fast Track和项目定位已有公司一手披露，今天缺少新增疗效量级和真实行情支持，暂不交易。
📄 原文Investing.com↗ 原文
BlossomHill to present BH-30643 lung cancer data at WCLC
Fed hike bets, oil rally and Japan yields - what’s moving markets SAN DIEGO - BlossomHill Therapeutics Inc. (NASDAQ:BLS…
不做 BlossomHill Therapeutics（BLSM.US）
不做：本次只是WCLC数据披露预告，未公布新增临床结果；Fast Track背景已于8月18日披露，且未取得真实行情报价，缺少可执行edge。
展开详情(成交明细 / 研究档案 / 原文全文 / 决策记录链)
研究档案
结论摘要
BH-30643针对EGFR C797S耐药NSCLC具备未满足需求和潜在商业价值，但本次Investing.com消息只确认9月15日WCLC将展示更新数据，未披露疗效、安全性或样本量等决定性新增事实；公司官网显示Fast Track和SOLARA项目背景已在8月18日披露，当前更适合作为9月15日读数前的观察事件，而不是立即开仓催化。
消息传播链
- Investing.com转述公司新闻称BH-30643更新数据将于2026年9月15日在WCLC报告；该节点是本轮信号来源，但不是临床数据披露本身。
- 公司此前已正式披露BH-30643获得FDA Fast Track designation，并介绍SOLARA试验和C797S适应症背景；说明本次新闻中的若干核心背景并非新增。
关键理由
- BH-30643若在C797S耐药NSCLC显示清晰抗肿瘤活性，理论上可切入目前无获批口服靶向药的人群。
- 当前公告只预告WCLC报告，尚未公布现有销售基数、可触达患者数、ORR/PFS或安全性数据，因此未能量化业绩增量。
主要风险
- 9月15日前市场可能只交易会议预期，实际数据若样本小或安全性不佳会出现见光死。
- BLSM为新上市临床期生物科技公司，估值主要依赖管线预期，缺少收入基数使事件弹性和回撤都更高。
反向证据
- 做多前查反向 · 来源 web · 日期 2026-09-01 · 影响 weakens
公开可见信息只确认未来报告安排，未找到已公布的新增ORR、PFS或安全性数据；削弱立即做多依据。
检索:BlossomHill BH-30643 SOLARA WCLC September 15 2026 updated data ORR safety 原文 ↗ - 做多前查反向 · 来源 web · 日期 2026-08-18 · 影响 weakens
Fast Track和无获批口服靶向疗法等关键背景已在两周前的一手IR稿中披露，今天的增量主要是会议排期。
检索:BlossomHill BH-30643 Fast Track C797S August 18 2026 原文 ↗
先例如何影响了这次决策
对本次决策的影响:先例不足强化不做结论，等待9月15日实际数据后再评估。
方向:未取得足够相似且锚点干净的临床会议数据预告先例；仅凭会议预告无法推导短线胜率。
涨幅量级:没有可用高相似先例和真实报价，不能校准tp/sl幅度。
形态:生物科技会议预告类事件常取决于实际读数质量，本次未披露数据，见光死风险只能作为风险而非交易依据。
工具执行结果 · 成功 2 · 降级 0 · 失败 0 · 取消 0
- web_search 成功 ? · 0 ms
- web_search 成功 ? · 0 ms
原文全文
展开原文 · 2,086 字
Fed hike bets, oil rally and Japan yields - what’s moving markets
SAN DIEGO - BlossomHill Therapeutics Inc. (NASDAQ:BLSM) announced Monday that updated data from its Phase 1/2 SOLARA trial will be presented on September 15, 2026 at the World Conference on Lung Cancer in Seoul, South Korea.
The mini-oral presentation will describe anti-tumor activity of BH-30643 in patients with secondary epidermal growth factor receptor resistance mutations, including EGFR C797S, according to a press release statement.
Dr. Hidehito Horinouchi from National Cancer Center Hospital in Tokyo will present the data on September 15 at 11:00 AM KST in a session titled "Closing The Gaps In Driver Altered NSCLC: Moving Beyond Current Boundaries."
BH-30643 received Fast Track designation from the FDA for treatment of C797S-positive resistance in EGFR-mutant non-small cell lung cancer. No oral targeted therapies are currently approved for this patient population.
The company stated that C797S represents a mechanism of resistance in EGFR-mutant lung cancer after progression on third-generation EGFR inhibitors such as osimertinib.
BH-30643 is an investigational, oral, non-covalent, macrocyclic, brain active, mutant-selective EGFR inhibitor. The drug candidate is being evaluated in the SOLARA trial, a global Phase 1/2 study spanning more than 40 sites in 10 countries.
The trial is assessing safety, tolerability, pharmacokinetics, pharmacodynamics and preliminary anti-tumor activity of BH-30643 in patients with EGFR-mutant non-small cell lung cancer. Ongoing dose expansion cohorts are enrolling in both TKI-pretreated and TKI-naive settings, including a C797S resistance cohort.
BlossomHill Therapeutics is a clinical-stage biopharmaceutical company headquartered in San Diego. The company is also developing BH-30236 for relapsed or refractory acute myeloid leukemia and higher-risk myelodysplastic syndrome, and has a preclinical program, BH-501284, targeting KRAS-mutant tumors.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.
SAN DIEGO - BlossomHill Therapeutics Inc. (NASDAQ:BLSM) announced Monday that updated data from its Phase 1/2 SOLARA trial will be presented on September 15, 2026 at the World Conference on Lung Cancer in Seoul, South Korea.
The mini-oral presentation will describe anti-tumor activity of BH-30643 in patients with secondary epidermal growth factor receptor resistance mutations, including EGFR C797S, according to a press release statement.
Dr. Hidehito Horinouchi from National Cancer Center Hospital in Tokyo will present the data on September 15 at 11:00 AM KST in a session titled "Closing The Gaps In Driver Altered NSCLC: Moving Beyond Current Boundaries."
BH-30643 received Fast Track designation from the FDA for treatment of C797S-positive resistance in EGFR-mutant non-small cell lung cancer. No oral targeted therapies are currently approved for this patient population.
The company stated that C797S represents a mechanism of resistance in EGFR-mutant lung cancer after progression on third-generation EGFR inhibitors such as osimertinib.
BH-30643 is an investigational, oral, non-covalent, macrocyclic, brain active, mutant-selective EGFR inhibitor. The drug candidate is being evaluated in the SOLARA trial, a global Phase 1/2 study spanning more than 40 sites in 10 countries.
The trial is assessing safety, tolerability, pharmacokinetics, pharmacodynamics and preliminary anti-tumor activity of BH-30643 in patients with EGFR-mutant non-small cell lung cancer. Ongoing dose expansion cohorts are enrolling in both TKI-pretreated and TKI-naive settings, including a C797S resistance cohort.
BlossomHill Therapeutics is a clinical-stage biopharmaceutical company headquartered in San Diego. The company is also developing BH-30236 for relapsed or refractory acute myeloid leukemia and higher-risk myelodysplastic syndrome, and has a preclinical program, BH-501284, targeting KRAS-mutant tumors.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.
决策记录链 · 只追加
每次领取产生一条记录,重新决策追加一条并以 supersedes 指向被替代的记录(ADR 0014)。
这条决策早于决策账本(2026-10-08 起逐条追加),没有追加记录。